Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamainternmed.2014.3139 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New Insights Into Hepatic Impairment (HI) Trials.
Clin Transl Sci
January 2025
Clinical Pharmacology, Translational Medicine and Clinical Pharmacology, Boehringer-Ingelheim Pharma, Ingelheim, Germany.
Hepatic impairment (HI) trials are traditionally part of the clinical pharmacology development to assess the need for dose adaptation in people with impaired metabolic capacity due to their diseased liver. This review aimed at looking into the data from dedicated HI studies, cluster these data into various categories and connect the effect by HI with reported pharmacokinetics (PK) properties in order to identify patterns that may allow waiver, extrapolations, or adapted HI study designs. Based on a ratio ≥ 2 or ≤ 0.
View Article and Find Full Text PDFChronic Low-Level IFN-γ Expression Disrupts Mitochondrial Complex I Activity in Renal Macrophages: An Early Mechanistic Driver of Lupus Nephritis Pathogenesis.
Int J Mol Sci
December 2024
Department of Food Science and Nutrition, Kyungpook National University, Daegu 41566, Republic of Korea.
Mitochondrial dysfunction and macrophage dysregulation are well recognized as significant contributors to the pathogenesis of autoimmune diseases. However, the detailed mechanisms connecting these two factors remain poorly understood. This study hypothesizes that low but chronic interferon-gamma (IFN-γ) plays a critical role in these processes.
View Article and Find Full Text PDFBioinformatics analysis of mitochondrial metabolism-related genes demonstrates their importance in renal cell carcinoma.
Discov Oncol
January 2025
Clinical Research and Development Center, Division of Nephrology, Department of Internal Medicine, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Purpose: Clear cell renal cell carcinoma (ccRCC) is resistant to radiotherapy and chemotherapy. Thus, it is necessary to find new diagnostic markers and therapeutic targets to increase the overall outcomes of ccRCC. Recent studies have shown that therapeutic methods that interfere with the energy transfer system can also positively affect the treatment process.
View Article and Find Full Text PDFHospitalized upper extremity artery disease patients: treatment and long-term outcomes.
Eur Heart J
December 2024
Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
Background And Aims: Current knowledge about upper extremity artery disease (UEAD) is scarce. This study aimed to evaluate the prevalence, treatment patterns, and short- and long-term outcomes of patients suffering from UEAD.
Methods: Retrospective health claims data of patients who were hospitalized with a primary diagnosis of UEAD between 2010 and 2017 were analysed.
Cerebral white matter damage in patients with end-stage kidney disease associates with cognitive impairment.
Clin Kidney J
January 2025
Healthy Aging Research Center, Chang Gung University, Taoyuan City, Taiwan.
Background: Damage to brain white matter often occurs in individuals with chronic kidney disease, which might be related to their cognitive decline. This study aims to investigate tract-specific white matter damage in patients with end-stage kidney disease by using fixel-based analysis.
Methods: Images of 31 end-stage kidney disease patients and 16 normal controls (aged: 61.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!